SSKN 8-K furnishes Q3 FY2025 results; Exhibit 99.1 provided
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
STRATA Skin Sciences furnished an 8-K to announce it issued a press release with results for the third fiscal quarter ended September 31, 2025. The press release is included as Exhibit 99.1.
The disclosures under Item 2.02 and Item 7.01, including Exhibit 99.1, are being furnished, not filed, which means they are not subject to Section 18 liability and are not incorporated into other filings unless specifically referenced.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 2.02, 7.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 13, 2025
(Exact Name of Registrant Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 215 -619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. |
Results of Operations and Financial Condition.
|
On November 13, 2025, STRATA Skin Sciences, Inc. (the “Company”)
issued a press release announcing its results of operations for the third fiscal quarter ended September 31, 2025. The full text of such press release is
furnished as Exhibit 99.1 to this report.
The information set forth under this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 7.01. |
Regulation FD Disclosure.
|
On November 13, 2025, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the
third fiscal quarter ended September 31, 2025. The full text of such press release is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be
deemed to be “filed”:
|
99.1
|
Press Release dated November 13, 2025 issued by STRATA Skin Sciences, Inc.
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
STRATA SKIN SCIENCES, INC.
|
|||
|
Date: November 13, 2025
|
By:
|
/s/ John Gillings
|
|
|
Chief Accounting Officer
|
|||
FAQ
What did SSKN announce in this 8-K?
The company furnished a press release with results for the third fiscal quarter ended September 31, 2025, as Exhibit 99.1.
Which items of the 8-K apply to SSKN’s disclosure?
Items 2.02 (Results of Operations and Financial Condition) and 7.01 (Regulation FD Disclosure).
Is the press release deemed filed or furnished?
It is furnished, not filed, and therefore not subject to Section 18 liability or automatically incorporated into other filings.
What exhibit contains SSKN’s Q3 press release?
Exhibit 99.1 contains the press release dated November 13, 2025.
When was the 8-K event date for SSKN?
November 13, 2025.
What is SSKN’s trading symbol and exchange?
Trading symbol SSKN on The Nasdaq Stock Market LLC.